Houston expert: Top three ways to make cybersecurity a business decision

guest column

A Houston founder explains why you should shift the way you think about cybersecurity from a cost to an investment in your business. Photo via Getty Images

For companies big or small, scaling your revenue securely is about building people, processes, and technology to help you deliver your value to market in the most efficient way possible. But shifting cybersecurity as a cost to an investment takes a shift in thinking.

Here are three tips to make cyber a business decision for your company.

Don’t fail at digital transformation. Whether you’re considering a digital “initiative” to stay ahead of competitors, reduce operational expenditure when possible, or simply drive efficiency to customer value delivery, transforming how you’re doing business should rest upon a foundation of security across your existing people, process, or technology. An effective cybersecurity program should drive confidence to your team to expand your tooling, processes, or delivery mechanisms with confidence. The alternate reality is you shift a working process to incorporate new technology, and something fails or breaks, causing frustration of your team and fewer dollars in the door. Here are a few tips that will help you make sound business investments in technology:

  1. New technology or system can introduce new cyber risks to your company. As a result, it is good practice to balance the value gained with the risks absorbed. Establishing a “new product” risk vs reward process will reduce ad hoc purchases and introduce more sound thinking to your team’s decisions.
  2. New technology purchases will come with vendor onboarding but beware of the challenges you face when those implementation or training hours run out. Ask for additional support hours as part of your purchase so that you’re always able to call a help desk for real support.

Secure design reduces long-term costs. Regardless of your business type, if some type of cyber-attack could affect your business outcome(s) — be it your product, the loss of sensitive customer data, theft of intellectual property, or disruption to service delivery — consider investments in your cyber program an investment towards the cost of future business operations.

For instance, manufacturers across virtually every sector continually balance “secure design” with efficiency/cost as they compete in the market. Their challenge: estimating future recalls and product “updates” to be paid for by future operational expenditure. The same can be applied to unforeseen downtime of a critical inventory, payment capture, or website system. In both cases, here are two tips to shift cyber from a “security cost” to a “business” mindset:

  1. Work with your security vendors to develop a long-term strategy rather than quoting an “install and leave” project. Security vendors are businesses too. They will respond positively if you tell them you will offer longevity in return for payment over time. 
  2. Amortize your costs this year into next year's costs of goods. If you can negotiate monthly or quarterly payments with your security vendors, adding 30-60 days of net pay dates, you’re already starting to shift security improvements realized tomorrow to costs you pay next quarter.

Your customers want you to have a great cyber program. Especially in regulated spaces like healthcare, defense, and other critical infrastructure sectors, there is a high chance your company’s cyber program must meet minimal cyber guidelines. Investing in the training, processes, and technology required to achieve some element of “compliance” is a must-have investment for doing business with big companies.

A mistake small companies make is allocating the minimal resources “reach the bar” without thinking about the risks. Employee turnover, scaling your business in new regions, and increasing purchase order sizes all carry a potential “new bar” you must reach on your cyber maturity. Building a cyber program initiative may help you increase sales. Imagine you say this in your next prospect meeting as you aim to win that big contract, “Additionally, we reviewed your cybersecurity supplier requirements online and are pleased to say we have certified documentation showcasing an evolving, continually improving cyber program that exceeds your requirements. We feel that adds to our differentiation.”

------

Ted Gutierrez is the CEO and co-founder of SecurityGate, a SaaS platform for OT cyber improvement.

From Your Site Articles
Three Houston startup founders took the stage to talk product/market fit, customer acquisition, funding, and the rest of the startup journey at a panel at SXSW. Photo courtesy of the GHP

Houston founders demystify startup journey on SXSW panel

Houston innovators podcast episode 177

Editor's note: On Monday at Houston House, a SXSW activation put on by the Greater Houston Partnership, I moderated a panel called “Demystifying the Startup Journey.” Panelists included three Houston founders: Ted Gutierrez, co-founder and CEO of SecurityGate.io, Simone May, co-founder and CTO of Clutch, and Gaurav Khandelwal, founder and CEO of Velostics. The three entrepreneurs discussed their journeys and the challenges they face — from product/market fit and hiring to fundraising and customer acquisition. Listen to the full conversation on this week’s episode of the Houston Innovators Podcast below. Thank you to SXSW and GHP for the recording.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings